SEC Comment Letter 0000000000-24-002245 to Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT)
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: Feb. 28, 2024 · CIK: 0001764013 · Accession: 0000000000-24-002245
AI Filing Summary & Sentiment
File numbers found in text: 001-38906
Letter
United States securities and exchange commission logo February 28, 2024 Eva Renee Barnett Chief Financial Officer Immunovant, Inc. 320 West 37th Street New York, NY 10018 Re:Immunovant, Inc. Form 10-K for the Fiscal Year Ended March 31, 2023 Filed May 22, 2023 File No. 001-38906 Dear Eva Renee Barnett: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
February 28, 2024
Eva Renee Barnett
Chief Financial Officer
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Re:Immunovant, Inc.
Form 10-K for the Fiscal Year Ended March 31, 2023
Filed May 22, 2023
File No. 001-38906
Dear Eva Renee Barnett:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences